OTCMKTS:IPHYF - Innate Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innate Pharma SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.90 0.00 (0.00 %) (As of 03/27/2020 04:00 PM ET) Add Compare Today's Range$4.90Now: $4.90▼$4.9050-Day Range$3.78MA: $6.62▼$7.7452-Week Range$3.70Now: $4.90▼$8.12VolumeN/AAverage Volume214 shsMarket Capitalization$384.85 millionP/E RatioN/ADividend YieldN/ABeta-0.19 ProfileAnalyst RatingsAdvanced ChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. In addition, it offers a commercial-stage product, Lumoxiti, an oncology product for treating hairy cell leukemia. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France.Read More Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IPHYF Previous SymbolNASDAQ:IPHYF CUSIPN/A CIKN/A Webhttp://www.innate-pharma.com/ Phone33-04-30-30-30-30Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$96.12 million Price / Sales4.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.23 per share Price / Book1.16Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees195 Outstanding Shares78,540,000Market Cap$384.85 million Next Earnings Date6/9/2020 (Estimated) OptionableNot Optionable Receive IPHYF News and Ratings via Email Sign-up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. OTC:IPHYF Rates by TradingView Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions How has Innate Pharma's stock been impacted by COVID-19 (Coronavirus)? Innate Pharma's stock was trading at $7.1690 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IPHYF stock has decreased by 31.7% and is now trading at $4.90. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Innate Pharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innate Pharma. When is Innate Pharma's next earnings date? Innate Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, June 9th 2020. View our earnings forecast for Innate Pharma. What price target have analysts set for IPHYF? 1 equities research analysts have issued 1 year price targets for Innate Pharma's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Innate Pharma's stock price to reach $11.00 in the next year. This suggests a possible upside of 124.5% from the stock's current price. View analysts' price targets for Innate Pharma. Has Innate Pharma been receiving favorable news coverage? Headlines about IPHYF stock have trended very negative on Saturday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innate Pharma earned a news sentiment score of -3.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutInnate Pharma. Who are some of Innate Pharma's key competitors? Some companies that are related to Innate Pharma include Zymeworks (ZYME), Theravance Biopharma (TBPH), Akcea Therapeutics (AKCA), Constellation Pharmaceuticals (CNST), Pacira Biosciences (PCRX), IGM Biosciences (IGMS), Karyopharm Therapeutics (KPTI), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), Corcept Therapeutics (CORT), Innoviva (INVA), Ligand Pharmaceuticals (LGND), Tricida (TCDA), I-Mab (ARQT) and TG Therapeutics (TGTX). What other stocks do shareholders of Innate Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include ADOCIA/S (ADOCY), Cellectis (CLLS), InVitae (NVTA), Allena Pharmaceuticals (ALNA), REDHILL BIOPHAR/S (RDHL), Arbutus Biopharma (ABUS), Obseva (OBSV), ZEALAND PHARMA/S (ZEAL), Granite Construction (GVA) and VICI Properties (VICI). Who are Innate Pharma's key executives? Innate Pharma's management team includes the following people: Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)Ms. Laure-Hélène Mercier, Exec. VP, CFO & Member of Exec. Board (Age 41)Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55) What is Innate Pharma's stock symbol? Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF." How do I buy shares of Innate Pharma? Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Innate Pharma's stock price today? One share of IPHYF stock can currently be purchased for approximately $4.90. How big of a company is Innate Pharma? Innate Pharma has a market capitalization of $384.85 million and generates $96.12 million in revenue each year. Innate Pharma employs 195 workers across the globe. View additional information about Innate Pharma. What is Innate Pharma's official website? The official website for Innate Pharma is http://www.innate-pharma.com/. How can I contact Innate Pharma? Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected] MarketBeat Community Rating for Innate Pharma (OTCMKTS IPHYF)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 124 (Vote Outperform)Underperform Votes: 98 (Vote Underperform)Total Votes: 222MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe IPHYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHYF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/28/2020 by MarketBeat.com StaffFeatured Article: What are retained earnings?
